Respiratory Failure With HypoxiaOptiproneNCT03095300
Prone Positioning During High Flow Oxygen Therapy in Acute Hypoxemic Respiratory Failure
A study testing Prone position in people with Respiratory Failure With Hypoxia and Respiratory Failure Without Hypercapnia, run by Catholic University of the Sacred Heart at 1 site in Italy.
Trial summary
Background High-flow nasal cannula (NHF) are a promising tool for administering oxygen to critically ill patients with high respiratory demand. Prone positioning (PP) is a simple and cost-effective strategy that since 1980s has been used in mechanically ventilated patients with acute respiratory failure to treat… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Respiratory Failure With Hypoxia, Respiratory Failure Without Hypercapnia
- What is being tested?
- Prone position
- Type of treatment
- Surgery or procedure
- How many people
- 15 participants
- Where
- 1 siteItaly
- Study dates
- 1 Oct 2018to 20 Dec 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Respiratory rate>25 bpm and <40 bpm.
- PaO2/FiO2<200 mmHg measured after 15 minutes of heated and humidified 50% oxygen at a rate of 50 l/min via a non-rebreathing face mask. Given the use of the high flows, nominal FiO2 will be considered a reliable estimate of the actual one.
- PaCO2 <45mmHg
- Absence of history of chronic respiratory failure or moderate to severe cardiac insufficiency (NYHA > II or left ventricular ejection fraction <50%).
- Body mass index <30 kg/m2
- Absence of any contraindication to prone position.
- Written informed consent
Who cannot join
- Exacerbation of asthma or chronic obstructive pulmonary disease (COPD);
- Chest trauma
- Cardiogenic pulmonary oedema;
- Severe Neutropenia (<500 WBC/mm3);
- Haemodynamic instability (Systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg) and/or lactic acidosis (lactate >5 mmol/L) and/or clinically diagnosed Shock
- Metabolic Acidosis (pH <7.30 with normal- or hypo-carbia);
Show all 9Show fewer
- Chronic kidney failure requiring dialysis before ICU admission;
- Glasgow coma scale <13;
- Vomiting and/or upper gastrointestinal bleeding.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prone Positioning During High Flow Oxygen Therapy in Patients With Acute Hypoxemic Respiratory Failure: a Pilot Physiological Trial
Background High-flow nasal cannula (NHF) are a promising tool for administering oxygen to critically ill patients with high respiratory demand.
Prone positioning (PP) is a simple and cost-effective strategy that since 1980s has been used in mechanically ventilated patients with acute respiratory failure to treat oxygenation impairment.
Read more
A large randomized study detected a relevant survival benefit by prone positioning in patients with moderate to severe acute respiratory distress syndrome (ARDS) undergoing invasive mechanical ventilation and managed with the ARDS network PEEP-FiO2 table strategy.
Theoretically, PP may benefit spontaneous breathing patients too, but data concerning its application in such context are limited to small case series and a retrospective study.
The investigators designed a pilot feasibility study to assess the safety and efficacy of prone positioning in acute hypoxemic respiratory failure patients noninvasively treated with NHF.
Methods Patients: 15 adult hypoxemic (PaO2/FiO2<200 mmHg with respiratory rate greater than 25 breaths per minute) non-hypercapnic patients with acute respiratory failure. PaO2/FiO2 will be assessed while the patients is receiving 50 L/min of 50% oxygen via a standard face mask for a 15-minute monitoring period at study entry.
Protocol Eligible patients will undergo NHF for 1 hour in the supine semi-recumbent position (baseline, BL).
Afterwards, each enrolled patient will be placed in the prone position for 2 hours.
After a 2-hour PP period, the patient will be rotated and will undergo 1 hour of NHF in the semi recumbent supine position (Supine step).
Measurements Patient's demographics will be collected at study entry.
At the end of the monitoring period, and then on a hourly basis the following data will be collected:
- Respiratory rate, SpO2, pH, PaCO2, PaO2, SaO2, PaO2/FiO2;
- Heart Rate, arterial blood pressure;
- Dyspnea, as defined by the VAS dyspnoea scale;
- Discomfort, as defined by a visual analogic scale (VAS) adapted to rate the procedural pain of ICU patients;
- End expiratory lung impedance (EELI), tidal volume distribution, global and regional lung dynamic strain (Change in lung impedence due to tidal volume/ELLI).
- Work of breathing, assessed by pressure-time product (PTP) of the esophageal pressure and inspiratory swings in this signal.
- Occurrence of pendelluft phenomenon
The number of adverse events will be also recorded for each study step.
Read the detailed description
Background Nasal high flow oxygen (NHF) is a new and promising tool for oxygen therapy in critically ill patients: NHF allows accurate delivery of the set FiO2, anatomical dead space clearance due to a washout effect in the upper airways and provides a small, variable amount of positive end end-expiratory pressure. Different studies have investigated its safety and efficacy in several clinical setting and, recently, a randomized controlled trial showed that NHF, as compared to NIV, may reduce the intubation rate in severely hypoxemic patients with de novo acute respiratory failure (AHRF).
Prone positioning (PP) is a simple and cost-effective strategy that since 1980s has been used in mechanically ventilated patients with acute respiratory failure to treat oxygenation impairment. In the acute respiratory distress syndrome (ARDS) PP reduces intrapulmonary shunt (Qs/Qt) and enhances lung recruitment, modifying both lung ventilation (VA) and lung perfusion (Q) distribution, finally generating an improvement in VA/Q matching and reversing oxygenation impairment. In addition, the reduction of transpulmonary gradient (mean pulmonary arterial pressure-pulmonary artery occlusion pressure) due to a higher pulmonary arterial occlusion pressure allows pulmonary vascular recruitment, possibly lowering dead space fraction. Indeed, prone positioning sessions have been shown to reduce right ventricular afterload, increase cardiac index in subjects with preload reserve and reverse acute cor pulmonale in severe ARDS patients. Finally, a large randomized study detected a relevant survival benefit by prone positioning in patients with moderate to severe acute respiratory distress syndrome (ARDS) undergoing invasive mechanical ventilation and managed with the ARDS network peep-FiO2 table strategy.
Theoretically, PP benefits may concern also spontaneous breathing patients, in whom it could possibly contribute to the success of the noninvasive strategy. Data concerning PP application in such context are limited to small case series and a retrospective study involving patients undergoing NIV or oxygen therapy and suggesting good patients tolerance, significant improvement in oxygenation during the procedure and no increase in nurse workload. In particular, in the retrospective study by Pesenti and co. 43 procedures in 15 patients were analysed: three patients (20%) received mild sedation without dosing adjustments over the course of the study, median [IqR] duration of prone positioning was 3[2-4] hours and only in two cases (5%) pronation had to be interrupted after 30 minutes due to patient's discomfort, while no other respiratory or technical complications, such as displacement of indwelling catheters, facial oedema, pressure sores, pressure neuropathies, compression of nerves, and retinal vessels or vomiting, have been documented. Given its high tolerability, simplicity to use and positive effect on patients' comfort when compared both to NIV and to low flow oxygen delivered through a face mask, NHF may be the optimal strategy for the respiratory management of spontaneous breathing patients during prone positioning.
Interestingly, a recent electrical impedance tomography study on 20 healthy volunteers during NHF showed a more homogeneous dorsal-to-ventral ventilation pattern in PP, as compared to the supine position: notably, a dorsal-to-ventral more uniform air distribution may benefit hypoxemic patients, given that PaO2 response to oxygen supplementation can be fostered by more homogeneous regional lung inflation and better oxygenation has been shown to be a predictor of NHF treatment success.
The investigators designed a pilot feasibility study to assess the safety and efficacy of prone positioning in patients wit AHRF undergoing high flow oxygen therapy via nasal cannula.
Methods:
Setting: 21-bed medical-surgical ICU, Fondazione Policlinico Universitario "Agostino Gemelli", Rome, Italy..
Patients: adult hypoxemic (PaO2/FiO2 < 200 mmHg) non-hypercapnic patients with acute respiratory failure will be assessed for the enrolment. To validate the presence of the oxygenation criteria, each eligible patient, in the absence of exclusion criteria, will receive 15 minutes of heated and humidified 50% oxygen at a rate of 50 l/min via a non-rebreathing face mask. An ABG will be then collected and PaO2/FiO2 ratio computed: given the high flows used, actual FiO2 will be approximated to the set one. Patients with a P/F ratio<80 mmHg and/or a RR>40 bpm will be excluded for safety reasons.
Protocol Eligible patients will undergo NHF for 1 hour in the supine semi recumbent position (baseline, BL step). Oxygen therapy will be commenced at 60 l/min and flows will be decreased in case of intolerance. Humidification chamber (MR860, Fisher and Paykel healthcare) will be set at 37 °C or 31 °C according to patient's comfort. FiO2 will be titrated to obtain and SpO2 >92 % and <98 %.
Afterwards, the patient will be placed in the prone position for 2 hours (Prone step). During pronation FiO2 will be increased up to 80% and then gradually decreased to the baseline value within the first 10 minutes of prone positioning. Any further modifications in the NHF settings will be discouraged over the entire course of the study; nonetheless, if needed to achieve the SpO2 target, an increase in FiO2 will be allowed and recorded.
As suggested by Pesenti and co., in conscious and cooperative patients pronation will be performed by 2 operators and the attending physician, while in patients with impaired mobility up to 5 operators will be necessary. Evaluation of gastric residual volume through a nasogastric tube will reduce the risk of aspiration and application of appropriate skin protections will avoid pressure sores. In addition, careful application of appropriate cushions will enhance patient tolerance to the manoeuvre.
For safety reasons, enteral feeding, whether prescribed, will be interrupted 1 hour before prone positioning and re-established after the study ending.
After a 2-hour PP period, the patient will be rotated and will undergo 1 hour of NHF in the semi recumbent supine position (Supine step).
As already stated, FiO2 will be increased up to 80% for the procedure and then gradually decreased to the baseline value within the following 10 minutes.
In case of intolerance to PP, all clinical data will be collected and the patients will be promptly rotated in supine position. The reasons for prematurely unproning the patient will be accurately recorded. In case of sudden worsening of the oxygenation impairment or haemodynamics, 100% FiO2 will be set and the patient will be promptly positioned in the supine semi-recumbent position.
Measurements Patient's demographics will be collected at study entry: initials, age, sex, height, weight, BMI, cause of hospital and ICU admission, SAPS II, Apache, SOFA, date and time of ICU admission, date and time of enrolment, comorbidities, NYHA category prior to respiratory failure, body temperature, chest x-ray (jpeg images), chest CT scan (if available).
At study enrolment an electrical impedance tomography (EIT) belt will be placed around the thorax between the 5th or 6th parasternal intercostal space and connected to a dedicated device to record electrical impedance signals.
During the study, each patient will undergo a standard ICU monitoring: ECG, Invasive blood pressure, SpO2, respiratory rate, diuresis.
At the end of the BL period, and then on a hourly basis the following data will be collected:
- Respiratory rate, SpO2, pH, PaCO2, PaO2, SaO2, PaO2/FiO2;
- Heart Rate, arterial blood pressure;
- Dyspnoea, as defined by the Borg dyspnoea scale;
- Discomfort, as defined by a visual analogic scale (VAS) adapted to rate the procedural pain of ICU patients;
- End expiratory lung impedance (EELI), tidal volume distribution and global and regional lung dynamic strain (Change in lung impedence due to tidal volume/EELI). At the end of each step, ten-minute EIT signals will be recorded and offline reviewed using a dedicated software. Image acquisition rate will be 30 Hz. Lungs will be divided into four regions (ventral, mid-ventral, mid-dorsal and dorsal): the percentage of impedance variation related to tidal volume and the percentage EELI in the four regions as compared to the absolute values will be calculated.
- PTP of the esophageal pressure
- Esophageal pressure inspiratory swings
- Respiratory system, lung and chest wall mechanics, according to the method proposed by Mauri et al. (Am J Resp Crit Care Med 2017)
- Pendelluft phenomenon
As a safety tool the following adverse events will be assessed in each of the three study periods:
- The number of displacements of the nasal cannula
- The number of oxygen desaturations (SpO2 <90%)
- Episodes of haemodynamic instability (Systolic arterial pressure<80 mmHg or FC>120 BPM)
- Displacement of venous line (peripheral or central), if documented
- Displacement of arterial line, if documented
- Displacement of urinary catheter, if documented.
At the end of the study, the nurse in charge will be asked to anonymously rate the additional workload due to PP (in minutes) and to judge the feasibility and safety of the procedure using two analog scales ranging from 0 (completely unfeasible/unsafe) to 10 (totally feasible/safe).
Sample size Given the pilot, physiological and exploratory design of the study, a formal sample power analysis was not performed. It is planned to enrol 15 patients over a period of 12 months.
- Being tested
- Prone position
- Keywords
- Prone Position, High-flow oxygen therapy
- Medical subject headings
- Respiratory Insufficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prone positionProcedure or surgery
Patients are rotated from the supine to the prone position for a period of 2 hours.
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients that undergo 2 hours of prone positioning without showing serious adverse events
Number of patients that tolerate the procedure and complete the study according to the protocol without serious adverse events. The following will be considered serious adverse events:
- Oxygen desaturations (SpO2 <90%)
- Episodes of haemodynamic instability (Systolic arterial pressure<80 mmHg or FC>120 BPM)
- Displacement of central venous line, if documented
- Displacement of arterial line, if documented
Measured: 2 hours
Oxygenation
Effects of prone position on oxygenation, defined by PaO2/FiO2 ratio
Measured: 2 hours
Secondary outcomes (17)
Respiratory rate
Effects of prone position on respiratory rate
Measured: 2 hours
Comfort
Effects of prone position on comfort, defined according a visual analog comfort scale
Measured: 2 hours
Dyspnoea
Effects of prone position on dyspnoea, defined according Borg dyspnea scale
Measured: 2 hours
Global impedance-derived End-expiratory lung volume
Effects of prone position on End-expiratory lung volume, measured with electrical impedance tomography
Measured: 2 hours
Regional impedance-derived End-expiratory lung volume
Effects of prone position on End-expiratory lung impedance in the four regions of the lungs (ventral, mid-ventral, mid-dorsal, dorsal), measured with electrical impedance tomography
Measured: 2 hours
Tidal volume distribution
Effect of prone position on % tidal volume distribution in the four regions of the lung (ventral, mid-ventral, mid-dorsal, dorsal), explored with electrical impedance tomography
Measured: 2 hours
Global impedance-derived lung dynamic strain
Change in impedance due to tidal volume / end expiratory lung impedance, both measured with electrical impedance tomography
Measured: 2 hours
Regional impedance-derived lung dynamic strain
Change in impedance due to tidal volume / end expiratory lung impedance in the four regions of the lungs (ventral, mid-ventral, mid-dorsal, dorsal), measured with electrical impedance tomography
Measured: 2 hours
Inspiratory effort
The esophageal pressure swings during inspiration
Measured: 2 hours
Respiratory mechanics
Respiratory system, lung and chest wall mechanics
Measured: 2 hours
Pendelluft
Occurrence of intra-tidal shift of gas within different lung regions at beginning of inspiration
Measured: 2 hours
Work of breathing
Pressure-time product of the esophageal pressure
Measured: 2 hours
Nurse workload
The nurse in charge will be asked to anonymously rate in minutes the additional workload due to the entire procedure (both proning and unproning)
Measured: 5 hours
Feasibility scale
At the end of the study, the nurse in charge will be asked to anonymously judge the feasibility of the procedure using an analog scale ranging from 0 (completely unfeasible) to 10 (totally feasible)
Measured: 5 hours
Safety scale
At the end of the study, the nurse in charge will be asked to anonymously to judge the safety of the procedure using an analog scale ranging from 0 (completely unsafe) to 10 (totally safe)
Measured: 5 hours
Prone-position related serious adverse events
Composite outcome, any of the following included:
- Oxygen desaturations (SpO2 <90%)
- Episodes of haemodynamic instability (Systolic arterial pressure<80 mmHg or FC>120 BPM)
- Displacement of central venous line, if documented
- Displacement of arterial line, if documented
Measured: 2 hours
Prone-position related adverse events
Composite outcome, any of the following included:
- Displacement of peripheral venous line, if documented
- Displacement of urinary catheter, if documented
- Displacement of oro- or naso-gastric tube, if documented
- Displacements of the nasal cannula, if any
Measured: 2 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Mar 2017
- Study start1 Oct 2018
- Primary completion20 Jun 2020
- Study completion20 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Respiratory Failure With HypoxiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Each enrolled patient will be monitored in the supine position for one hour, placed in the prone position for two hours and re-placed in the supine position for a final 1-hour step
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Catholic University of the Sacred Heart
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Massimo Antonelli, Catholic University of the Sacred Heart
- Investigators
- Massimo Antonelli, MD, Principal investigator, Catholic University of the Sacred Heart
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03095300
- Sponsor's protocol ID
- Optiprone
- Acronym
- Optiprone
- Status last verified
- Aug 2022
- First submitted
- 14 Mar 2017
- Last updated
- 3 Aug 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Grieco DL, Delle Cese L, Menga LS, Rosa T, Michi T, Lombardi G, Cesarano M, Giammatteo V, Bello G, Carelli S, Cutuli SL, Sandroni C, De Pascale G, Pesenti A, Maggiore SM, Antonelli M. Physiological effects of awake prone position in acute hypoxemic respiratory failure. Crit Care. 2023 Aug 17;27(1):315. doi: 10.1186/s13054-023-04600-9.
PubMed 37592288
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prone Positioning During High Flow Oxygen Therapy in Patients With Acute Hypoxemic Respiratory Failure: a Pilot Physiological Trial
- ClinicalTrials.gov ID
- NCT03095300
- Acronym / sponsor ID
- Optiprone / Optiprone
- Keywords
- Prone Position, High-flow oxygen therapy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Catholic University of the Sacred HeartUniversity, hospital or other
- Study start
- 1 Oct 2018 (actual)
- Primary completion
- 20 Jun 2020 (actual)
- Study completion
- 20 Dec 2020 (actual)
- First posted
- 29 Mar 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background High-flow nasal cannula (NHF) are a promising tool for administering oxygen to critically ill patients with high respiratory demand.
Prone positioning (PP) is a simple and cost-effective strategy that since 1980s has been used in mechanically ventilated patients with acute respiratory failure to treat oxygenation impairment.
A large randomized study detected a relevant survival benefit by prone positioning in patients with moderate to severe acute respiratory distress syndrome (ARDS) undergoing invasive mechanical ventilation and managed with the ARDS network PEEP-FiO2 table strategy.
Theoretically, PP may benefit spontaneous breathing patients too, but data concerning its application in such context are limited to small case series and a retrospective study.
The investigators designed a pilot feasibility study to assess the safety and efficacy of prone positioning in acute hypoxemic respiratory failure patients noninvasively treated with NHF.
Methods Patients: 15 adult hypoxemic (PaO2/FiO2<200 mmHg with respiratory rate greater than 25 breaths per minute) non-hypercapnic patients with acute respiratory failure. PaO2/FiO2 will be assessed while the patients is receiving 50 L/min of 50% oxygen via a standard face mask for a 15-minute monitoring period at study entry.
Protocol Eligible patients will undergo NHF for 1 hour in the supine semi-recumbent position (baseline, BL).
Afterwards, each enrolled patient will be placed in the prone position for 2 hours.
After a 2-hour PP period, the patient will be rotated and will undergo 1 hour of NHF in the semi recumbent supine position (Supine step).
Measurements Patient's demographics will be collected at study entry.
At the end of the monitoring period, and then on a hourly basis the following data will be collected:
- Respiratory rate, SpO2, pH, PaCO2, PaO2, SaO2, PaO2/FiO2;
- Heart Rate, arterial blood pressure;
- Dyspnea, as defined by the VAS dyspnoea scale;
- Discomfort, as defined by a visual analogic scale (VAS) adapted to rate the procedural pain of ICU patients;
- End expiratory lung impedance (EELI), tidal volume distribution, global and regional lung dynamic strain (Change in lung impedence due to tidal volume/ELLI).
- Work of breathing, assessed by pressure-time product (PTP) of the esophageal pressure and inspiratory swings in this signal.
- Occurrence of pendelluft phenomenon
The number of adverse events will be also recorded for each study step.
Detailed description
Background Nasal high flow oxygen (NHF) is a new and promising tool for oxygen therapy in critically ill patients: NHF allows accurate delivery of the set FiO2, anatomical dead space clearance due to a washout effect in the upper airways and provides a small, variable amount of positive end end-expiratory pressure. Different studies have investigated its safety and efficacy in several clinical setting and, recently, a randomized controlled trial showed that NHF, as compared to NIV, may reduce the intubation rate in severely hypoxemic patients with de novo acute respiratory failure (AHRF).
Prone positioning (PP) is a simple and cost-effective strategy that since 1980s has been used in mechanically ventilated patients with acute respiratory failure to treat oxygenation impairment. In the acute respiratory distress syndrome (ARDS) PP reduces intrapulmonary shunt (Qs/Qt) and enhances lung recruitment, modifying both lung ventilation (VA) and lung perfusion (Q) distribution, finally generating an improvement in VA/Q matching and reversing oxygenation impairment. In addition, the reduction of transpulmonary gradient (mean pulmonary arterial pressure-pulmonary artery occlusion pressure) due to a higher pulmonary arterial occlusion pressure allows pulmonary vascular recruitment, possibly lowering dead space fraction. Indeed, prone positioning sessions have been shown to reduce right ventricular afterload, increase cardiac index in subjects with preload reserve and reverse acute cor pulmonale in severe ARDS patients. Finally, a large randomized study detected a relevant survival benefit by prone positioning in patients with moderate to severe acute respiratory distress syndrome (ARDS) undergoing invasive mechanical ventilation and managed with the ARDS network peep-FiO2 table strategy.
Theoretically, PP benefits may concern also spontaneous breathing patients, in whom it could possibly contribute to the success of the noninvasive strategy. Data concerning PP application in such context are limited to small case series and a retrospective study involving patients undergoing NIV or oxygen therapy and suggesting good patients tolerance, significant improvement in oxygenation during the procedure and no increase in nurse workload. In particular, in the retrospective study by Pesenti and co. 43 procedures in 15 patients were analysed: three patients (20%) received mild sedation without dosing adjustments over the course of the study, median [IqR] duration of prone positioning was 3[2-4] hours and only in two cases (5%) pronation had to be interrupted after 30 minutes due to patient's discomfort, while no other respiratory or technical complications, such as displacement of indwelling catheters, facial oedema, pressure sores, pressure neuropathies, compression of nerves, and retinal vessels or vomiting, have been documented. Given its high tolerability, simplicity to use and positive effect on patients' comfort when compared both to NIV and to low flow oxygen delivered through a face mask, NHF may be the optimal strategy for the respiratory management of spontaneous breathing patients during prone positioning.
Interestingly, a recent electrical impedance tomography study on 20 healthy volunteers during NHF showed a more homogeneous dorsal-to-ventral ventilation pattern in PP, as compared to the supine position: notably, a dorsal-to-ventral more uniform air distribution may benefit hypoxemic patients, given that PaO2 response to oxygen supplementation can be fostered by more homogeneous regional lung inflation and better oxygenation has been shown to be a predictor of NHF treatment success.
The investigators designed a pilot feasibility study to assess the safety and efficacy of prone positioning in patients wit AHRF undergoing high flow oxygen therapy via nasal cannula.
Methods:
Setting: 21-bed medical-surgical ICU, Fondazione Policlinico Universitario "Agostino Gemelli", Rome, Italy..
Patients: adult hypoxemic (PaO2/FiO2 < 200 mmHg) non-hypercapnic patients with acute respiratory failure will be assessed for the enrolment. To validate the presence of the oxygenation criteria, each eligible patient, in the absence of exclusion criteria, will receive 15 minutes of heated and humidified 50% oxygen at a rate of 50 l/min via a non-rebreathing face mask. An ABG will be then collected and PaO2/FiO2 ratio computed: given the high flows used, actual FiO2 will be approximated to the set one. Patients with a P/F ratio<80 mmHg and/or a RR>40 bpm will be excluded for safety reasons.
Protocol Eligible patients will undergo NHF for 1 hour in the supine semi recumbent position (baseline, BL step). Oxygen therapy will be commenced at 60 l/min and flows will be decreased in case of intolerance. Humidification chamber (MR860, Fisher and Paykel healthcare) will be set at 37 °C or 31 °C according to patient's comfort. FiO2 will be titrated to obtain and SpO2 >92 % and <98 %.
Afterwards, the patient will be placed in the prone position for 2 hours (Prone step). During pronation FiO2 will be increased up to 80% and then gradually decreased to the baseline value within the first 10 minutes of prone positioning. Any further modifications in the NHF settings will be discouraged over the entire course of the study; nonetheless, if needed to achieve the SpO2 target, an increase in FiO2 will be allowed and recorded.
As suggested by Pesenti and co., in conscious and cooperative patients pronation will be performed by 2 operators and the attending physician, while in patients with impaired mobility up to 5 operators will be necessary. Evaluation of gastric residual volume through a nasogastric tube will reduce the risk of aspiration and application of appropriate skin protections will avoid pressure sores. In addition, careful application of appropriate cushions will enhance patient tolerance to the manoeuvre.
For safety reasons, enteral feeding, whether prescribed, will be interrupted 1 hour before prone positioning and re-established after the study ending.
After a 2-hour PP period, the patient will be rotated and will undergo 1 hour of NHF in the semi recumbent supine position (Supine step).
As already stated, FiO2 will be increased up to 80% for the procedure and then gradually decreased to the baseline value within the following 10 minutes.
In case of intolerance to PP, all clinical data will be collected and the patients will be promptly rotated in supine position. The reasons for prematurely unproning the patient will be accurately recorded. In case of sudden worsening of the oxygenation impairment or haemodynamics, 100% FiO2 will be set and the patient will be promptly positioned in the supine semi-recumbent position.
Measurements Patient's demographics will be collected at study entry: initials, age, sex, height, weight, BMI, cause of hospital and ICU admission, SAPS II, Apache, SOFA, date and time of ICU admission, date and time of enrolment, comorbidities, NYHA category prior to respiratory failure, body temperature, chest x-ray (jpeg images), chest CT scan (if available).
At study enrolment an electrical impedance tomography (EIT) belt will be placed around the thorax between the 5th or 6th parasternal intercostal space and connected to a dedicated device to record electrical impedance signals.
During the study, each patient will undergo a standard ICU monitoring: ECG, Invasive blood pressure, SpO2, respiratory rate, diuresis.
At the end of the BL period, and then on a hourly basis the following data will be collected:
- Respiratory rate, SpO2, pH, PaCO2, PaO2, SaO2, PaO2/FiO2;
- Heart Rate, arterial blood pressure;
- Dyspnoea, as defined by the Borg dyspnoea scale;
- Discomfort, as defined by a visual analogic scale (VAS) adapted to rate the procedural pain of ICU patients;
- End expiratory lung impedance (EELI), tidal volume distribution and global and regional lung dynamic strain (Change in lung impedence due to tidal volume/EELI). At the end of each step, ten-minute EIT signals will be recorded and offline reviewed using a dedicated software. Image acquisition rate will be 30 Hz. Lungs will be divided into four regions (ventral, mid-ventral, mid-dorsal and dorsal): the percentage of impedance variation related to tidal volume and the percentage EELI in the four regions as compared to the absolute values will be calculated.
- PTP of the esophageal pressure
- Esophageal pressure inspiratory swings
- Respiratory system, lung and chest wall mechanics, according to the method proposed by Mauri et al. (Am J Resp Crit Care Med 2017)
- Pendelluft phenomenon
As a safety tool the following adverse events will be assessed in each of the three study periods:
- The number of displacements of the nasal cannula
- The number of oxygen desaturations (SpO2 <90%)
- Episodes of haemodynamic instability (Systolic arterial pressure<80 mmHg or FC>120 BPM)
- Displacement of venous line (peripheral or central), if documented
- Displacement of arterial line, if documented
- Displacement of urinary catheter, if documented.
At the end of the study, the nurse in charge will be asked to anonymously rate the additional workload due to PP (in minutes) and to judge the feasibility and safety of the procedure using two analog scales ranging from 0 (completely unfeasible/unsafe) to 10 (totally feasible/safe).
Sample size Given the pilot, physiological and exploratory design of the study, a formal sample power analysis was not performed. It is planned to enrol 15 patients over a period of 12 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Model description
- Each enrolled patient will be monitored in the supine position for one hour, placed in the prone position for two hours and re-placed in the supine position for a final 1-hour step
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Respiratory rate>25 bpm and <40 bpm.
- PaO2/FiO2<200 mmHg measured after 15 minutes of heated and humidified 50% oxygen at a rate of 50 l/min via a non-rebreathing face mask. Given the use of the high flows, nominal FiO2 will be considered a reliable estimate of the actual one.
- PaCO2 <45mmHg
- Absence of history of chronic respiratory failure or moderate to severe cardiac insufficiency (NYHA > II or left ventricular ejection fraction <50%).
- Body mass index <30 kg/m2
Key exclusion criteria (9 listed)
- Exacerbation of asthma or chronic obstructive pulmonary disease (COPD);
- Chest trauma
- Cardiogenic pulmonary oedema;
- Severe Neutropenia (<500 WBC/mm3);
- Haemodynamic instability (Systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg) and/or lactic acidosis (lactate >5 mmol/L) and/or clinically diagnosed Shock
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Prone positionPatients are rotated from the supine to the prone position for a period of 2 hours. | Procedure or surgery | – |
Primary outcome
Number of patients that undergo 2 hours of prone positioning without showing serious adverse events
Time frame: 2 hours
Number of patients that tolerate the procedure and complete the study according to the protocol without serious adverse events. The following will be considered serious adverse events: * Oxygen desaturations (SpO2 <90%) * Episodes of haemodynamic instability (Systolic arterial pressure<80 mmHg or FC>120 BPM) * Displacement of central venous line, if documented * Displacement of arterial line, if documented
Oxygenation
Time frame: 2 hours
Effects of prone position on oxygenation, defined by PaO2/FiO2 ratio
17 secondary outcomes
Respiratory rate
Time frame: 2 hours
Comfort
Time frame: 2 hours
Dyspnoea
Time frame: 2 hours
Global impedance-derived End-expiratory lung volume
Time frame: 2 hours
Regional impedance-derived End-expiratory lung volume
Time frame: 2 hours
Tidal volume distribution
Time frame: 2 hours
Global impedance-derived lung dynamic strain
Time frame: 2 hours
Regional impedance-derived lung dynamic strain
Time frame: 2 hours
Inspiratory effort
Time frame: 2 hours
Respiratory mechanics
Time frame: 2 hours
Pendelluft
Time frame: 2 hours
Work of breathing
Time frame: 2 hours
Nurse workload
Time frame: 5 hours
Feasibility scale
Time frame: 5 hours
Safety scale
Time frame: 5 hours
Prone-position related serious adverse events
Time frame: 2 hours
Prone-position related adverse events
Time frame: 2 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2022.
- Derived from this study: PubMed 37592288Grieco DL, Delle Cese L, Menga LS, Rosa T, Michi T, Lombardi G, Cesarano M, Giammatteo V, Bello G, Carelli S, Cutuli SL, Sandroni C, De Pascale G, Pesenti A, Maggiore SM, Antonelli M. Physiological effects of awake prone position in acute hypoxemic respiratory failure. Crit Care. 2023 Aug 17;27(1):315. doi: 10.1186/s13054-023-04600-9.
- Individual participant dataSharing planned: Undecided
Related trials for Respiratory Failure With Hypoxia
Recruiting
Automated Oxygen Titration With the EMILY.AI Device in a Respiratory Intermediate Care Unit
Chronic Respiratory Failure, Acute Respiratory Failure
Active, not recruiting
Delayed Cord Clamping With Oxygen In Extremely Low Gestation Infants
IVH- Intraventricular Hemorrhage, Extreme Prematurity
Recruiting
Identifying the Best Flow Setting Strategy for High-Flow Nasal Cannula
Extubation Readiness, Respiratory Failure With Hypoxia
Recruiting
Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia
Chronic Respiratory Failure, Hypoxemia
Active, not recruiting
Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic
SARS-CoV-2 Infections, Respiratory Failure With Hypoxia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Massimo Antonelli, MD principal investigator
Catholic University of the Sacred Heart
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Prone position in people with Respiratory Failure With Hypoxia and Respiratory Failure Without Hypercapnia, run by Catholic University of the Sacred Heart at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients that undergo 2 hours of prone positioning without showing serious adverse events (time frame: 2 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03095300, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2022.